Recruiting
An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany - CA209-1210
Actualizada: 17 abril, 2024 | ClinicalTrials.gov
Géneros
Rango de edad
Ubicación (es)
Recruiting
Inclusion Criteria: - Aged 18 years or older - Diagnosis of non-metastatic non-small cell lung cancer with tumor Programmed death-ligand 1 (PD-L1) expression level of 1% or more (tumor proportion score (TPS); according to label approved in the European Union) - Decision to initiate a neoadjuvant treatment with nivolumab plus platinum-based chemotherapy for treatment of non-small cell lung cancer according to current Summary of product characteristics and independent of the study - Willing to complete patient-reported outcome questionnaires and sufficient understanding of the German language - Signed written informed consent - Other criteria according to current Summary of product characteristics Exclusion Criteria: - Current primary diagnosis of cancer other than non-small cell lung cancer that requires systemic or other treatment - Other contraindications according to current Summary of product characteristics
